Recent Quotes (30 days)

You have no recent quotes
chg | %

Healthcare News

Showing stories 1 - 10 of about 70   
Johnson & Johnson's 2018 forecast impresses before 'disappointing'
Without acquisitions and divestitures, J&J expects organic sales growth to be in the range of 2.5 percent to 3.5 percent. Including those deals, operational sales growth will be 3.5 percent to 4.5 percent.
Johnson & Johnson loses $10.7B after sweeping US tax changes  Chicago Tribune
Johnson & Johnson Earnings: When Strong Isn't Strong Enough  Barron's
Johnson & Johnson falls on 'disappointing' sales outlook
Shares of Johnson & Johnson turned negative as investors reacted to a lackluster sales growth outlook. The company topped Wall Street's fourth-quarter earnings and revenue expectations with boosts from new cancer drugs and its acquisition of Swiss ...
Johnson & Johnson withdraws pelvic mesh device from Australian market
Pharmaceutical giant Johnson & Johnson has withdrawn from the Australian market its supply of the vaginal mesh device that is the subject of a class action before the federal court.
Johnson & Johnson Has Withdrawn The Mesh Products It Is Being Sued Over  BuzzFeed News
Johnson & Johnson earnings: Expect a strong quarter for drug sales
A researcher works at the laboratory of the research and development plant of US multinational medical devices and pharmaceutical company Johnson & Johnson, in northwestern France.
Johnson & Johnson Results Driven by Pharmaceutical Sales Growth
Johnson & Johnson JNJ -4.26% sales rose in the fourth quarter, but the company reported a loss after taking a $13.6 billion charge as a result of the new U.S.
Talcum Powder Lawsuits Move Forward Against Johnson & Johnson, As Mesothelioma ...
NEW YORK, Jan. 23, 2018 /PRNewswire/ -- Another talcum powder lawsuit is heading to trial, as jury selection for a case involving the alleged link between Johnson & Johnson's talc-based powders and a deadly form of cancer called mesothelioma began ...
US appeals court upholds ruling invalidating Johnson & Johnson patent on ...
An appeals court affirmed a previous ruling that a Johnson & Johnson patent covering the active ingredient in Remicade was invalid because it was based on an obvious concept.
Johnson & Johnson Loses Appeal on Validity of Remicade Patent  Bloomberg
Mesh victims celebrate 'extraordinary' move by American pharmaceutical giant
Finally: Robyn Ramster, of Valentine, was pleased to hear Johnson & Johnson had withdrawn its "gold standard" incontinence mesh slings from the Australian market after severe complications following mesh surgery in 2005.
Should Income Investors Buy Pfizer Inc (NYSE:PFE) Before Its Ex-Dividend?
On the 01 March 2018, Pfizer Inc (NYSE:PFE) will be paying shareholders an upcoming dividend amount of $0.34 per share. However, investors must have bought the company's stock before 01 February 2018 in order to qualify for the payment.
Analyst's Predictions on Facebook, Inc. (FB), Pfizer Inc. (PFE)  StockNewsJournal
Pfizer Inc. (PFE) Closes 0.3% Down on the Day for January 23  Equities.com
Johnson & Johnson is trying to sell its diabetes care business to Chinese ...
Johnson & Johnson, the world's largest health care company, is seeking to sell off its diabetes care businesses, including LifeScan, Animas, and Calibra.